Figure 1. Diagram of patient disposition.

A total of 60 non–small cell lung cancer (NSCLC) patients, who started nivolumab treatment as second-line or further-line treatment from January 2016 to May 2017 were enrolled in this cohort. Of those, 11 could be followed up over 8 weeks after nivolumab discontinuation, and ultimately 9 patients were followed-up over the long term. Follow-up study design and schedules are presented in Supplemental Table 1. Five patients from period 2 were selected as representatives for transcriptome analysis.